Core Viewpoint - The company,健世科技-B (09877), has seen its stock price increase by over 8% following the announcement of regulatory approvals for its medical devices in New Zealand [1] Group 1: Product Approvals - The company announced that its Ken-Valve transcatheter aortic valve replacement system and LuX-ValvePlus transcatheter tricuspid valve replacement system have received registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to accelerate the commercialization of these products in New Zealand [1] Group 2: Market Recognition - The company highlighted that the Ken-Valve and LuX-ValvePlus have gained widespread market recognition due to their design advantages, ongoing clinical trials, and continuous promotion of therapies [1] - This recognition is seen as a positive factor in the company's strategy to enhance its global commercialization efforts [1] Group 3: Strategic Goals - The company aims to further its long-term strategic goals by expediting the global commercialization process of its product portfolio following the recent approvals [1]
健世科技-B涨超8% 两款核心治疗心脏瓣膜疾病产品获新西兰注册批准